BioWorld

Sep. 14, 2007

Isis Gets $45M Up Front In Deal With Ortho On Diabetes Drugs

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today) Read More

Genmab's 'Turnaround' Year Includes More Cancer Focus

More Is More For Receptor Tyrosine Kinase Inhibitors

PTC Gets $20M Investment From Celgene For Oncology Targets

Cell Therapy Company Aldagen Adds $9M To Series C Financing

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for May 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...

APAC monitors hantavirus as Singapore isolates 2 from cruise ship

BioWorld

Singapore’s Communicable Diseases Agency on May 7 said that it isolated two residents for hantavirus testing after the individuals disembarked from an Atlantic...